Novel Technologies for percutaneous treatment of tricuspid valve regurgitation Percutaneous transcatheter tricuspid valve treatment: a clinical and technical challenge
Tricuspid regurgitation (TR) is mostly secondary to annular dilatation and/or leaflet tethering, in the absence of organic valve lesions or, as a result of left-sided heart valve disease, atrial fibrillation, or pulmonary hypertension, [functional TR (FTR) ].
Isolated tricuspid surgery is usually carried out with a very high morbidity and mortality, [1] [2] [3] resulting in a large number of untreated patients. 4 Percutaneous procedures have been emerging as an attractive alternative to surgery. 5 Although feasibility has been shown with several devices, clinical experience is still very preliminary and only limited data are available to support any evidence of clinical efficacy.
This review will summarize the specific challenges of transcatheter tricuspid valve interventions (TTVI) and the available technologies which are currently under evaluation.
Clinical challenges Patient selection and interventional timing
Although it has been shown that the presence of severe TR is independently associated with poor outcomes, 6, 7 it is questionable Figure 4 Indication for TAVI in 2025. A possible scenario in the near future may be that recommendations for TAVI are no longer based on classical risk stratification but are made according to age and some specific co-morbidities. This is provided that TAVI in forthcoming trials of low-risk patients will have positive results, and that long-term data will confirm similar durability between transcatheter heart valves and surgical bioprostheses. TAVI, transcatheter aortic valve implantation.
whether correction of severe TR can provide a prognostic benefit, especially in the presence of advanced heart failure. At this stage, most TTVI are performed as a compassionate treatment in inoperable end-stage patients with advanced heart failure, right ventricular (RV) dysfunction and severe comorbidities. In these circumstances, it is extremely difficult to assess the real clinical benefits of any treatment. This underlines the importance of proper interventional timing, to achieve a prognostic benefit and to avoid futile procedures. Severe RV failure and severe pulmonary hypertension should represent contraindications to TTVI. However, since at the moment there are no data to clearly define which patient could benefit from an intervention, multidisciplinary heart team discussion is mandatory for each case.
Anatomical challenges Technical and interventional perspectives
A detailed knowledge of the anatomy of the TV is fundamental to understand the specific challenges related to TTVI. Here below are listed the most important differences with the mitral valve and their interventional implications:
(1) The TV is approached though the inferior vena cava (IVC) or through a transjugular/trans-subclavian venous approach. The absence of trans-septal support and the short distance between the IVC orifice and the TV annulus results in a lack of stabilization and difficult coaxiality to the TV plane. (2) Intraprocedural transoesophageal echocardiography (TEE) guidance is particularly challenging, due to the more anterior position of the TV compared with the mitral.
(3) The TV orifice is much larger compared with the mitral one (up to 9 cm 2 area in normal conditions, but much larger in the presence of functional TR). A complete obliteration of the regurgitant area can be extremely difficult or even impossible with any of the current devices. (4) The proximity of other cardiac structures: AV node, right coronary artery, aortic valve, coronary sinus. (5) The leaflets and chordal tissues are thinner and more frail compared with the mitral valve.
The challenge of intra-procedural guidance
Intra-procedural guidance remains a major issue of TTVI, because in many patients the echocardiographic window for the TV is suboptimal. Two-dimensional (2D) and three-dimensional (3D) TEE plays an essential role to guide TTVI. In particular, procedural guidance with 3D-TEE represents a fundamental tool to navigate in the right atrium.
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When the quality of intra-procedural guidance is suboptimal, a combination of TTE and intra-cardiac echocardiography (ICE) may represent a useful complementary tool to guide the intervention. TTE may be of additional help in MitraClip procedures to assess leaflet insertion; ICE may be of value in annuloplasty technique to visualize the leaflet-annulus hinge.
Preliminary clinical experiences with transcatheter tricuspid valve interventions
The devices that have been developed for TTVI can be divided according to the aimed therapeutic target: leaflet devices, annuloplasty devices, heterotopic caval valve implantation (CAVI) and transcatheter tricuspid valve replacement (Figure 1) . 
Leaflet devices MitraClip in tricuspid
The MitraClip V R system (Abbott Vascular, Santa Clara, CA, USA) has been successfully used for treating severe TR in selected patients.
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The transfemoral access has become the preferred route today.
Different to the mitral position, in which the therapeutic target to clip has a variable location according to the valve anatomy and corresponds to the site of origin of the mitral regurgitation, in FTR, regurgitation is usually central, with a huge defect of coaptation. Therefore, the rationale behind tricuspid clipping is to reduce the effective regurgitant orifice area (EROA) by 'closing' part of the valve, performing a form of 'annuloplasty with a leaflet device'. In most of the cases this is obtained by closing the antero-septal commissure, which is the easiest to target ('zipping by clipping').
Nickenig et al.
11 recently reported promising 30-day outcomes in a series of 64 high-risk patients with severe FTR, treated with tricuspid clipping. Significant reduction in TR and clinical improvements were observed.
FORMA Tricuspid Spacer
The FORMA Repair System (Edwards Lifesciences, Irvine, CA, USA) is composed of two parts: a spacer, which is positioned into the regurgitant orifice creating a platform for native leaflet to coapt, and a rail anchored at the right ventricle apex, which ensure device fixation. 12 Introduced through a venous subclavian access, after the final positioning, it is proximally locked at the subclavian region. The clinical outcomes (up to 1 year) of the first 18 patients have been recently reported (Perlman G., EuroPCR 2017, Paris, France). Acute TR reduction of at least one grade was achieved in 89% patients, with an extremely low incidence of adverse events. Significant improvements in functional status and reverse remodelling of the RV were observed at follow-up.
Annuloplasty devices Trialign
The Trialign device (Mitralign, Inc. Tewksbury, MA, USA) allows the operator to perform a transcatheter bicuspidization of the TV through a transvenous jugular approach, reproducing the surgical Kay bicuspidization technique. 13 One or multiple pairs of pledgets can be implanted. The SCOUT I feasibility trial included 15 patients with severe TR who underwent tricuspid annuloplasty with the Trialign. 13 The device was successfully implanted in all cases, with only one procedural complication (new right coronary stenosis requiring coronary stenting). At 30-day follow-up, survival was 100%, with a technical success rate of 80% (three single pledget dehiscence). No major adverse events were observed. Significant reduction in the tricuspid annular area and the EROA, as well as improvement in functional class and quality of life, was maintained up to 6 months.
Cardioband
The Cardioband system (Edwards Lifescience, Irvine, CA, USA) is a sutureless and adjustable surgical-like Dacron band, which is delivered through a percutaneous transfemoral approach and implanted on the atrial side of the tricuspid annulus by means of multiple anchor elements. After implantation, the size of the implant can be reduced in a reversible fashion, to reduce the annular dimension and increase leaflet coaptation. Safety and feasibility of Cardioband implantation in mitral position has been shown in high-risk patients with functional MR. 14,15 Preliminary results from the early feasibility trial in the tricuspid position have been recently presented (Kuck KH. EuroPCR 2017, Paris, France). Among 20 patients with severe FTR treated so far, a 27% reduction of septolateral tricuspid annular dimension has been reported. At 30 days, core-lab adjudicated data (available for a minority of patients) showed a reduction of TR, with significant improvement in symptoms and quality of life.
TriCinchTM
The TriCinch (4Tech Cardio, Galway, Ireland) is a catheter-based device designed to cinch the tricuspid annulus, improving leaflet coaptation and reducing TR. 16 Through a transfemoral access, a corkscrew element is implanted in the anterior tricuspid annulus. Once the corkscrew is secured, the system is retrieved and a self-expandable nitinol stent is introduced over the wire and coupled to the implant. The whole system is then tensioned to reshape the TV and to increase the leaflet coaptation, under live echo guidance. Finally, the stent is deployed in the IVC to maintain the tension applied. Among 24 patients treated in the PREVENT feasibility trial, the device was successfully implanted in 85% patients. No patient died at 30 days, and a reduction of at least one grade in TR was observed in 94% of the cases. Late anchor detachment was observed in 4 patients. To overcome the issue of tissue retention, a secondgeneration device is currently under pre-clinical evaluation (Denti P. EuroPCR 2017, Paris, France).
Millipede
The Millipede system (Millipede, LLC, Ann Arbor, MI, USA) is a fully repositionable and retrievable complete ring, which can be implanted surgically or transcatheter on the atrial side of the native tricuspid annulus, to restore its shape and diameter. First-in-man implant in mitral position has been surgically performed in 2015. So far, two patients had concomitant tricuspid valve repair, showing tricuspid diameter reductions of 42-45%, with no post-procedural residual TR (Rogers J. TVT 2017, Chicago, IL, USA).
Caval valve implantation
An alternative approach to percutaneous treatment of TV is to implant a transcatheter prosthesis in IVC (single valve approach) or in combination with a superior vena cava (SVC) valve (dual valve) to prevent damage to the liver and other organs. A dedicated a selfexpandable nitinol prosthesis named TricValve (P þ F Products Features Vertriebs GmbH, Vienna, Austria and Braile Biomedica, Sao José do Rio Preto, Brazil) has been specifically developed for the low-pressure venous circulation and to seal the large lumen of both superior and inferior venae cavae. Two bioprosthetic valves are available, with sizes ranging from 28 to 43 mm (up to 38 mm for superior vena cava, 43 mm for inferior vena cava).
Results from a multicentre registry including 23 patients have been recently reported (Lauten A. EuroPCR 2017, Paris, France) . Thirtyday survival was 82.6%; long-term survival was reported in eight patients with an overall median survival 98 days. Early valve migration requiring surgical intervention occurred in one patient.
Transcatheter tricuspid valve replacement Feasibility of tricuspid valve-in-valve and valve-in-ring has been shown with different devices and approaches. 17, 18 The only device that has been used to perform transcatheter tricuspid valve replacement in human with native tricuspid anatomy is the NaviGate self-expandable tricuspid valved stent (NaviGate Cardiac Structures Inc, Laguna Hills, CA, USA). It is a nitinol-tapered stent with three xenogeneic pericardial leaflets. Annular winglets enable fixation of the annulus and the leaflets. Two implants have been reported, one through trans atrial and 1 through trans jugular approach, with mild residual paravalvular TR and both patients are alive up to 5 months after the implantation.
(Navia JL. EuroPCR 2017, Paris, France).
Reporting outcomes after TTVI: towards, Tricuspid Valve Academic Research Consortium
The analysis of preliminary results from the early feasibility trials with the different devices raises the issue of how to report outcomes after TTVI. Patients consistently report improvements in quality of life measures despite only modest reductions in TR, according to the conventional definitions. Given the discordance between TR reduction and clinical improvement, it is evident that we cannot use definitions of procedural success for the TV that is used for aortic and mitral valves. This observation raises the need to define appropriate outcomes in this patient population and develop standard definitions on how to evaluate and report outcomes.
Conclusions
Although TTVI is still at a very early stage, initial results have shown feasibility and safety with different techniques and devices. Promising clinical improvements have been observed, but clinical efficacy has still to be proven. Patient selection, anatomical eligibility, and optimal procedural timing will be subjects of further investigation in the coming years. Defining appropriate outcomes and developing standard definitions on how to report procedural and patients' success will be a crucial step to assess efficacy of TTVI compared with optimal medical therapy.
